MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)

Who May Qualify: - Other than having HIV-1, is in good health - Is antiretroviral therapy (ART)-naïve - If ART-experienced has not received any antiretroviral therapy within 60 days (or 5 half-lives, whichever is longer) prior to screening - Is willing to receive no other ART prior to Day 8 post-dose of the trial - If capable of producing sperm agrees to use contraception - If assigned female sex at birth is not breastfeeding - A participant of childbearing potential (POCBP) is not pregnant and has a negative highly sensitive pregnancy test (urine or serum), and uses a contraceptive method that is highly effective Who Should NOT Join This Trial: - Has acute (primary) HIV-1 infection - Has history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases - Is mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years. - Has history of cancer (malignancy) - Has history of significant multiple and/or severe allergies - Tests positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies - Has had a major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit - Has received any vaccine starting from 30 days prior to study intervention or is scheduled to receive any vaccine through 14 days following study intervention - Is unable to refrain from using protocol specified prohibited medications - Is an excessive smoker, or consumes excessive amounts of alcoholic or caffeinated beverages - Is a regular user of any illicit drugs or has a history of drug (including alcohol) abuse Always talk to your doctor about whether this trial is right for you.